Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana.
Clin Gastroenterol Hepatol. 2017 Feb;15(2):166-174. doi: 10.1016/j.cgh.2016.10.024.
The purpose of this expert review is to synthesize the existing evidence on the management of Clostridium difficile infection in patients with underlying inflammatory bowel disease. The evidence reviewed in this article is a summation of relevant scientific publications, expert opinion statements, and current practice guidelines. This review is a summary of expert opinion in the field without a formal systematic review of evidence. Best Practice Advice 1: Clinicians should test patients who present with a flare of underlying inflammatory bowel disease for Clostridium difficile infection. Best Practice Advice 2: Clinicians should screen for recurrent C difficile infection if diarrhea or other symptoms of colitis persist or return after antibiotic treatment for C difficile infection. Best Practice Advice 3: Clinicians should consider treating C difficile infection in inflammatory bowel disease patients with vancomycin instead of metronidazole. Best Practice Advice 4: Clinicians strongly should consider hospitalization for close monitoring and aggressive management for inflammatory bowel disease patients with C difficile infection who have profuse diarrhea, severe abdominal pain, a markedly increased peripheral blood leukocyte count, or other evidence of sepsis. Best Practice Advice 5: Clinicians may postpone escalation of steroids and other immunosuppression agents during acute C difficile infection until therapy for C difficile infection has been initiated. However, the decision to withhold or continue immunosuppression in inflammatory bowel disease patients with C difficile infection should be individualized because there is insufficient existing robust literature on which to develop firm recommendations. Best Practice Advice 6: Clinicians should offer a referral for fecal microbiota transplantation to inflammatory bowel disease patients with recurrent C difficile infection.
本专家综述旨在综合现有关于潜在炎症性肠病患者艰难梭菌感染管理的证据。本文回顾的证据是对相关科学出版物、专家意见陈述和当前实践指南的总结。这篇综述是对该领域专家意见的总结,而没有对证据进行正式的系统评价。
最佳实践建议 1:出现潜在炎症性肠病发作的患者,临床医生应检测艰难梭菌感染。
最佳实践建议 2:艰难梭菌感染抗生素治疗后腹泻或其他结肠炎症状持续或复发时,临床医生应筛查复发性艰难梭菌感染。
最佳实践建议 3:临床医生应考虑使用万古霉素而非甲硝唑治疗炎症性肠病患者的艰难梭菌感染。
最佳实践建议 4:对于艰难梭菌感染的炎症性肠病患者,如果出现大量腹泻、严重腹痛、外周血白细胞计数明显增加或其他败血症证据,强烈建议住院密切监测和积极治疗。
最佳实践建议 5:在开始艰难梭菌感染治疗之前,临床医生可以考虑推迟急性艰难梭菌感染期间类固醇和其他免疫抑制剂的升级。然而,在艰难梭菌感染的炎症性肠病患者中是否停用或继续免疫抑制应个体化,因为目前还没有足够的强有力文献来制定明确的建议。
最佳实践建议 6:对于复发性艰难梭菌感染的炎症性肠病患者,临床医生应提供粪便微生物群移植的转介。